Navigating diagnostic and treatment decisions in non-small-cell lung cancer: expert commentary on the multidisciplinary team approach

Lung Cancer

Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.

1Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts

★ 1 Recommended by Dr Wolf-Dieter Janthur, Faculty Member

Lung Cancer.

Früh M, Panje CM, Reck M, Blackhall F, Califano R, Cappuzzo F, Besse B, Novello S, Garrido P, Felip E, O'Brien M, Paz Ares L, de Marinis F, Westeel V, De Ruysscher D, Putora PM

doi: 10.1016/j.lungcan.2020.03.024.

Lung, Respiratory and Thoracic Cancer

Alternative Multidisciplinary Management Options for Locally Advanced Non-Small Cell Lung Cancer During the COVID-19 Global Pandemic

J Thorac Oncol.

Kumar S, Chmura S, Robinson C, Lin SH, Gadgeel SM, Donington J, Feliciano J, Stinchcombe TE, Werner-Wasik M, Edelman MJ, Moghanaki D

doi: 10.1016/j.jtho.2020.04.016.

Lung, Respiratory and Thoracic Cancer

Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial

JAMA Oncol.

Miyamoto S, Azuma K, Ishii H, Bessho A, Hosokawa S, Fukamatsu N, Kunitoh H, Ishii M, Tanaka H, Aono H, Nakahara Y, Kusaka K, Hosomi Y, Kikuchi N, Mori Y, Itani H, Hamada A, Yamada K, Okamoto H

doi: 10.1001/jamaoncol.2020.1250.

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy

★ 1 Recommended by Dr Wolf-Dieter Janthur, Faculty Member

Lung Cancer.

Reck M, Syrigos K, Miliauskas S, Zöchbauer-Müller S, Fischer JR, Buchner H, Kitzing T, Kaiser R, Radonjic D, Kerr K

doi: 10.1016/j.lungcan.2020.08.004.

Lung, Respiratory and Thoracic Cancer

Comparison of early tumour-associated versus late deaths in patients with central or >7 cm T4 N0/1 M0 non-small-cell lung-cancer undergoing trimodal treatment: Only few risks left to improve

Eur J Cancer.

Guberina N, Pöttgen C, Schuler M, Guberina M, Stamatis G, Plönes T, Krebs B, Metzenmacher M, Theegarten D, Gauler T, Jöckel KH, Darwiche K, Aigner C, Stuschke M, Eberhardt WE

doi: 10.1016/j.ejca.2020.07.025.

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Immunotherapy for the first-line treatment of patients with metastatic non-small cell lung cancer

Clin Cancer Res.

Martinez P, Peters S, Stammers T, Soria JC

doi: 10.1158/1078-0432.CCR-

Lung, Respiratory and Thoracic Cancer

Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer

Lung Cancer.

Paz-Ares LG, Pérol M, Ciuleanu TE, Kowalyszyn RD, Reck M, Lewanski CR, Syrigos K, Arrieta O, Prabhash K, Park K, Pikiel J, Göksel T, Lee P, Zimmermann A, Cuyun Carter G, Alexandris E, Garon EB

Lung, Respiratory and Thoracic Cancer

Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial

J Thorac Oncol.

Nishio M, Barlesi F, West H, Ball S, Bordoni R, Cobo M, Longeras PD, Goldschmidt J Jr, Novello S, Orlandi F, Sanborn RE, Szalai Z, Ursol G, Mendus D, Wang L, Wen X, McCleland M, Hoang T, Phan S, Socinski MA

doi: 10.1016/j.jtho.2020.11.025.

Related content

Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.

Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts

Alternative Multidisciplinary Management Options for Locally Advanced Non-Small Cell Lung Cancer During the COVID-19 Global Pandemic

Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial

Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy

Comparison of early tumour-associated versus late deaths in patients with central or >7 cm T4 N0/1 M0 non-small-cell lung-cancer undergoing trimodal treatment: Only few risks left to improve

Immunotherapy for the first-line treatment of patients with metastatic non-small cell lung cancer

Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer

Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial